Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

3307 results

Sort By:

Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®

Study ID: NCT06504966
Start Date: 2025-10
End Date: 2027-10
Study Type

Interventional

Study Phase

Phase3

No. of Participants

440

Intervention / Treatment

MAB-22

Prolia®

Sponsor

Xentria, Inc.

Source: clinicaltrials.gov

Share:
Add to list

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

Study ID: NCT06525766
Start Date: 2025-10-15
End Date: 2030-10-15
Study Type

Interventional

Study Phase

Phase2

No. of Participants

35

Intervention / Treatment

Biospecimen Collection

Bone Scan

Capecitabine

Computed Tomography

Magnetic Resonance Imaging

Administration questionnaire

Sponsor

Mayo Clinic

Source: clinicaltrials.gov

Share:
Add to list

A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)

Study ID: NCT06891066
Start Date: 2025-04-21
End Date: 2027-10-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

150

Intervention / Treatment

ISL

Head

BIC/FTC/TAF

Sponsor

Merck Sharp & Dohme LLC

Source: clinicaltrials.gov

Share:
Add to list

Work at Heights Training: Conventional Approach With and Without Immersive Virtual Reality

Study ID: NCT06728566
Start Date: 2025-05
End Date: 2026-06
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

20

Intervention / Treatment

Inmersive virtual reality

Conventional training

Sponsor

Autonomous University of the West

Source: clinicaltrials.gov

Share:
Add to list

Closing the GAPS: Guideline Adherence, Prevention and Surveillance in Hereditary Cancer

Study ID: NCT06654466
Start Date: 2025-09-01
End Date: 2027-09
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

100

Intervention / Treatment

Nest, an electronic medical record (EMR)-integrated software platform to deliver longitudinal, genetics-based care at scale.

Sponsor

Nest Genomics

Source: clinicaltrials.gov

Share:
Add to list

Towards a Targeted Ultrasound Neuromodulation Intervention for Alcohol Abuse Disorders

Study ID: NCT06894966
Start Date: 2025-04-20
End Date: 2026-09-20
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

30

Intervention / Treatment

low intensity transcranial focused ultrasound stimulation (TUS)

Sponsor

University of Plymouth

Source: clinicaltrials.gov

Share:
Add to list

Effectiveness of Video Monitoring and Care Transition for Heart Failure Patients (EVIT-HF): Randomized Clinical Trial

Study ID: NCT06731166
Start Date: 2025-06-01
End Date: 2028-06-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

500

Intervention / Treatment

self-care

Sponsor

Federal University of Uberlandia

Source: clinicaltrials.gov

Share:
Add to list

Pilot Evaluation of a Psychoeducation Group for Family Caregivers of Children and Adolescents With Emotional and Behavioral Disorders (CPG-CA) in China

Study ID: NCT06900465
Start Date: 2025-06-01
End Date: 2026-04-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

30

Intervention / Treatment

Caregiver Psychoeducation Group for Children and Adolescents with Emotional and Behavioral Disorders (CPG-CA)

Sponsor

Shanghai Mental Health Center

Source: clinicaltrials.gov

Share:
Add to list

Early Intervention

Study ID: NCT05326165
Start Date: 2025-05
End Date: 2026-06-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

40

Intervention / Treatment

Juzo Compression Sleeve and Glove

Compression Sleeve Sensor

Sponsor

Massachusetts General Hospital

Source: clinicaltrials.gov

Share:
Add to list

Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone

Study ID: NCT06865365
Start Date: 2025-05-01
End Date: 2028-02-01
Study Type

Interventional

Study Phase

Phase4

No. of Participants

72

Intervention / Treatment

Liraglutide daily (0.6-3.0mg, highest tolerable dose) additional to dietological measures and lifestyle optimization suggestions

Dietologic measures and lifestyle optimization for weight loss

Sponsor

Medical University of Vienna

Source: clinicaltrials.gov

Share:
Add to list